XML 45 R34.htm IDEA: XBRL DOCUMENT
v3.20.2

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Segment Reporting [Abstract] |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] | A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited condensed consolidated statements of operations is as follows (in millions, except percentages):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Net sales | 2020 |  | 2019 |  | 2020 |  | 2019
MedSurg | $ | 825 |  |  | $ | 845 |  | $ | 2,175 |  |  | $ | 2,429
Rhythm and Neuro | 757 |  |  | 780 |  | 1,985 |  |  | 2,323
Cardiovascular | 1,002 |  |  | 1,058 |  | 2,862 |  |  | 3,057
Total net sales of reportable segments | 2,584 |  |  | 2,684 |  | 7,021 |  |  | 7,807
All other (Specialty Pharmaceuticals) | 74 |  |  | 23 |  | 183 |  |  | 23
Consolidated net sales | $ | 2,659 |  |  | $ | 2,707 |  | $ | 7,204 |  |  | $ | 7,831
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Income (loss) before income taxes | 2020 |  | 2019 |  | 2020 |  | 2019
MedSurg | $ | 307 |  |  | $ | 319 |  | $ | 738 |  |  | $ | 870
Rhythm and Neuro | 165 |  |  | 166 |  | 296 |  |  | 488
Cardiovascular | 208 |  |  | 283 |  | 593 |  |  | 860
Total operating income of reportable segments | 680 |  |  | 768 |  | 1,628 |  |  | 2,218
All other (Specialty Pharmaceuticals) | 49 |  |  | 13 |  | 124 |  |  | 13
Unallocated amounts: |  |  |  |  |  |  |
Corporate expenses, including hedging activities | (108) |  |  | (75) |  | (330) |  |  | (215)
Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits | (629) |  |  | (146) |  | (957) |  |  | (210)
Amortization expense | (197) |  |  | (178) |  | (595) |  |  | (498)
Operating income (loss) | (205) |  |  | 383 |  | (130) |  |  | 1,308
Other expense, net | (22) |  |  | (292) |  | (256) |  |  | (615)
Income (loss) before income taxes | $ | (227) |  |  | $ | 91 |  | $ | (386) |  |  | $ | 693
Operating income of reportable segments as a percentage of net sales of reportable segments | Three Months Ended September 30, |  | Nine Months Ended September 30,
2020 |  | 2019 |  | 2020 |  | 2019
MedSurg | 37.2 | % |  | 37.8 | % |  | 33.9 | % |  | 35.8 | %
Rhythm and Neuro | 21.9 | % |  | 21.3 | % |  | 14.9 | % |  | 21.0 | %
Cardiovascular | 20.8 | % |  | 26.7 | % |  | 20.7 | % |  | 28.1 | %

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration